Hao Qi, Rathinaswamy Manoj K, Klinge Kelly L, Bratkowski Matthew, Mafi Amirhossein, Baumgartner Christina K, Hamel Keith M, Veits Gesine K, Jain Rinku, Catalano Claudio, Fitzgerald Mark, Hird Alexander W, Park Eunice, Vora Harit U, Henderson James A, Longenecker Kenton, Hutchins Charles W, Qiu Wei, Scapin Giovanna, Sun Qi, Stoll Vincent S, Sun Chaohong, Li Ping, Eaton Dan, Stokoe David, Fisher Stewart L, Nasveschuk Christopher G, Paddock Marcia, Kort Michael E
Calico Life Sciences LLC, South San Francisco, CA, 94080, USA.
AbbVie, 1 North Waukegan Rd, North Chicago, IL, 60064, USA.
Commun Chem. 2024 Aug 16;7(1):183. doi: 10.1038/s42004-024-01263-7.
PTPN2 (protein tyrosine phosphatase non-receptor type 2, or TC-PTP) and PTPN1 are attractive immuno-oncology targets, with the deletion of Ptpn1 and Ptpn2 improving response to immunotherapy in disease models. Targeted protein degradation has emerged as a promising approach to drug challenging targets including phosphatases. We developed potent PTPN2/N1 dual heterobifunctional degraders (Cmpd-1 and Cmpd-2) which facilitate efficient complex assembly with E3 ubiquitin ligase CRL4, and mediate potent PTPN2/N1 degradation in cells and mice. To provide mechanistic insights into the cooperative complex formation introduced by degraders, we employed a combination of structural approaches. Our crystal structure reveals how PTPN2 is recognized by the tri-substituted thiophene moiety of the degrader. We further determined a high-resolution structure of DDB1-CRBN/Cmpd-1/PTPN2 using single-particle cryo-electron microscopy (cryo-EM). This structure reveals that the degrader induces proximity between CRBN and PTPN2, albeit the large conformational heterogeneity of this ternary complex. The molecular dynamic (MD)-simulations constructed based on the cryo-EM structure exhibited a large rigid body movement of PTPN2 and illustrated the dynamic interactions between PTPN2 and CRBN. Together, our study demonstrates the development of PTPN2/N1 heterobifunctional degraders with potential applications in cancer immunotherapy. Furthermore, the developed structural workflow could help to understand the dynamic nature of degrader-induced cooperative ternary complexes.
蛋白酪氨酸磷酸酶非受体2型(PTPN2,又称TC-PTP)和蛋白酪氨酸磷酸酶非受体1型(PTPN1)是颇具吸引力的免疫肿瘤学靶点,在疾病模型中删除Ptpn1和Ptpn2可增强对免疫疗法的反应。靶向蛋白降解已成为一种有前景的方法,用于攻克包括磷酸酶在内的具有挑战性的靶点。我们开发了强效的PTPN2/N1双功能异源降解剂(化合物1和化合物2),它们有助于与E3泛素连接酶CRL4高效组装复合物,并在细胞和小鼠中介导强效的PTPN2/N1降解。为了深入了解降解剂引入的协同复合物形成机制,我们采用了多种结构方法。我们的晶体结构揭示了降解剂的三取代噻吩部分如何识别PTPN2。我们还使用单颗粒冷冻电子显微镜(cryo-EM)确定了DDB1-CRBN/化合物1/PTPN2的高分辨率结构。该结构表明,尽管该三元复合物存在较大的构象异质性,但降解剂可诱导CRBN和PTPN2接近。基于冷冻电镜结构构建的分子动力学(MD)模拟显示PTPN2存在较大的刚体运动,并阐明了PTPN2与CRBN之间的动态相互作用。总之,我们的研究展示了PTPN2/N1双功能异源降解剂的开发及其在癌症免疫治疗中的潜在应用。此外,所开发的结构工作流程有助于理解降解剂诱导的协同三元复合物的动态性质。